By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: MEDEZE Receives Frost & Sullivan’s 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Entertainment > MEDEZE Receives Frost & Sullivan’s 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
MEDEZE Receives Frost & Sullivan’s 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
Entertainment

MEDEZE Receives Frost & Sullivan’s 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine

PRNW Agency
Last updated: 15/12/2025 7:36 PM
PRNW Agency
Published: 15/12/2025
Share
SHARE

The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence across Southeast Asia

- Advertisement -

SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that MEDEZE Group Public Company Limited (MEDEZE) has been honored with the 2025 Southeast Asia Company of the Year Recognition in the stem cell banking and regenerative medicine industry for its outstanding achievements in innovation, regulatory leadership, and clinical alignment. This recognition highlights MEDEZE’s leadership in advancing the next generation of personalized healthcare solutions while maintaining the highest global standards in safety, technology, and compliance.

- Advertisement -

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. MEDEZE excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with precision and scale. “MEDEZE is redefining stem cell banking in Southeast Asia through full-spectrum, clinically aligned solutions, leveraging innovation, regulatory leadership, and GMP-grade infrastructure to lead the transition from cell preservation to personalized medical application,” said Unmesh Lal, Vice President, Healthcare & Life Sciences at Frost & Sullivan.

- Advertisement -

Driven by a long-term strategy focused on innovation, clinical readiness, and international expansion, MEDEZE has built one of the region’s most comprehensive and technologically advanced cell banking ecosystems. Its vertically integrated model—spanning biological material collection, diagnostics, cell processing, storage, expansion, and clinical application—ensures consistent quality, regulatory compliance, and scalability across Southeast Asia.

- Advertisement -

Innovation is central to MEDEZE’s success. Proprietary technologies, such as the AutoXpress System for fully automated cord blood processing and the Chibuya Robotic Stem Cell Culture System (the world’s first full-room cleanroom automation), enable therapeutic-grade manufacturing at scale. The company’s AI-powered Hair Follicle Restoration platform and exclusive NK cell diagnostic technologies from Japan demonstrate its ability to extend cell applications into clinical and aesthetic care.

- Advertisement -

MEDEZE’s commitment to international accreditation and operational excellence strengthens its leadership in regenerative medicine. It is the only Thai stem cell bank accredited by the US-based Association for the Advancement of Blood & Biotherapies (AABB) and holds ISO 9001 and ISO 22716 certifications. These accreditations reinforce the company’s compliance with the highest safety and quality standards across both therapeutic and wellness applications.

- Advertisement -

Supported by a network of over 260 hospital partners, including leading institutions such as Samitivej Hospital Group and Bangkok Hospital, MEDEZE plays a central role in Thailand’s ADMP Sandbox clinical program. Through ongoing trials in osteoarthritis, degenerative disc disease, skin rejuvenation, colorectal cancer, and immune enhancement, MEDEZE is positioned to become one of the first private companies in Southeast Asia to commercialize licensed cell therapies by 2026.

- Advertisement -

Frost & Sullivan commends MEDEZE for setting a new benchmark in competitive strategy, innovation, and market responsiveness. Its integrated operational model, financial strength, and commitment to sustainable growth exemplify leadership in biotechnology and position it at the forefront of Southeast Asia’s transition toward licensed regenerative therapies.

- Advertisement -

Each year, Frost & Sullivan presents the Company of the Year Recognition to an organization that demonstrates outstanding strategy development and execution, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition celebrates forward-thinking companies that are redefining their industries through innovation and growth excellence.

- Advertisement -

Frost & Sullivan Best Practices Recognition
Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

- Advertisement -

Contact:
Tarini Singh
E: Tarini.Singh@frost.com 

- Advertisement -

Photo – https://mma.prnewswire.com/media/2845192/MEDEZE_award.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/medeze-receives-frost–sullivans-2025-southeast-asia-company-of-the-year-recognition-for-leadership-in-stem-cell-banking-and-regenerative-medicine-302641909.html

- Advertisement -
Brighty Launches Cashback Service for Crypto Cards, Offering Up to 1.75% Back
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
HTX Hot Listings Weekly Recap (Dec 29 – Jan 4): PEPE Leads Memecoin Frenzy as Multi-Chain Memecoins Surge
Bybit Stands With Its Community: Stability, Stable Income, and a Long-Term Commitment Through the Downturn
WBBA Releases Global Net5.5G Readiness Assessment and Certification Standards, and Huawei Unveils Upgraded Net5.5G IP Bearer Network Offerings to Boost New Industry Vitality
TAGGED:2025andasiabankingcellcompanyforfrostleadershipmedezemedicinenewsreceivesrecognitionregenerativesoutheaststemsullivan’stheyear
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Aurora Mobiles GPTBots.ai Integrates Grok 4 to Expand its Enterprise-Grade AI Agents Ecosystem
Technology

Aurora Mobiles GPTBots.ai Integrates Grok 4 to Expand its Enterprise-Grade AI Agents Ecosystem

GlobeNews Wire
GlobeNews Wire
28/07/2025
Anteris DurAVR THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
Bold Luxury: Bob Mackie, Stage Glamour & The Couture Edit
The Avestagenome Project and ‘Longevity India’ Initiative of Indian Institute of Science (IISc) Sign Landmark Agreement
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?